CN1939413B - 一种复方北豆根药物组合物 - Google Patents
一种复方北豆根药物组合物 Download PDFInfo
- Publication number
- CN1939413B CN1939413B CN2005100447660A CN200510044766A CN1939413B CN 1939413 B CN1939413 B CN 1939413B CN 2005100447660 A CN2005100447660 A CN 2005100447660A CN 200510044766 A CN200510044766 A CN 200510044766A CN 1939413 B CN1939413 B CN 1939413B
- Authority
- CN
- China
- Prior art keywords
- andrographolide
- rhizoma menispermi
- injection
- extract
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 21
- 150000001875 compounds Chemical class 0.000 title description 2
- 239000007924 injection Substances 0.000 claims abstract description 101
- 238000002347 injection Methods 0.000 claims abstract description 101
- 239000000284 extract Substances 0.000 claims abstract description 94
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 208000015181 infectious disease Diseases 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 239000002253 acid Substances 0.000 claims description 20
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 11
- AQASRZOCERRGBL-UHFFFAOYSA-N Dauricine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C1CC1=CC=C(O)C(OC2=CC=C(C=C2)CC2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-UHFFFAOYSA-N 0.000 claims description 10
- AQASRZOCERRGBL-ROJLCIKYSA-N dauricine Chemical compound CN1CCC2=CC(OC)=C(OC)C=C2[C@H]1CC1=CC=C(O)C(OC2=CC=C(C=C2)C[C@H]2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-ROJLCIKYSA-N 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 5
- 229930013930 alkaloid Natural products 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 3
- 230000002879 macerating effect Effects 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 206010013786 Dry skin Diseases 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 38
- 230000036039 immunity Effects 0.000 abstract description 3
- 241000245050 Menispermum Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000002249 digestive system Anatomy 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 139
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 139
- 229940090044 injection Drugs 0.000 description 98
- 238000012360 testing method Methods 0.000 description 32
- 229940079593 drug Drugs 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 20
- 239000008187 granular material Substances 0.000 description 17
- 239000000890 drug combination Substances 0.000 description 14
- 239000008215 water for injection Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 239000008354 sodium chloride injection Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 229920001214 Polysorbate 60 Polymers 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 11
- 238000012856 packing Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- -1 ester monopotassium salt Chemical class 0.000 description 9
- 239000011265 semifinished product Substances 0.000 description 9
- 239000008227 sterile water for injection Substances 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 210000003371 toe Anatomy 0.000 description 8
- 241000712461 unidentified influenza virus Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 235000010418 carrageenan Nutrition 0.000 description 7
- 229920001525 carrageenan Polymers 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 206010035664 Pneumonia Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 239000000679 carrageenan Substances 0.000 description 5
- 229940113118 carrageenan Drugs 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000007910 chewable tablet Substances 0.000 description 4
- 229940068682 chewable tablet Drugs 0.000 description 4
- 238000005262 decarbonization Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000009287 sand filtration Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- XOMKZKJEJBZBJJ-UHFFFAOYSA-N 1,2-dichloro-3-phenylbenzene Chemical group ClC1=CC=CC(C=2C=CC=CC=2)=C1Cl XOMKZKJEJBZBJJ-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000746375 Andrographis Species 0.000 description 2
- APIHNXDZCYDPTF-UHFFFAOYSA-N Daurinolin Natural products CN1CCC2=CC(OC)=C(OC)C=C2C1CC1=CC=C(O)C(OC2=CC=C(C=C2)CC2C=3C=C(C(=CC=3CCN2C)O)OC)=C1 APIHNXDZCYDPTF-UHFFFAOYSA-N 0.000 description 2
- BURJAQFYNVMZDV-FIRIVFDPSA-N Daurisoline Chemical compound CN1CCC2=CC(OC)=C(OC)C=C2[C@H]1CC(C=C1)=CC=C1OC1=CC(C[C@H]2N(C)CCC=3C=C(C(=CC=32)O)OC)=CC=C1O BURJAQFYNVMZDV-FIRIVFDPSA-N 0.000 description 2
- BURJAQFYNVMZDV-UHFFFAOYSA-N Daurisoline Natural products CN1CCC2=CC(OC)=C(OC)C=C2C1CC(C=C1)=CC=C1OC1=CC(CC2N(C)CCC=3C=C(C(=CC=32)O)OC)=CC=C1O BURJAQFYNVMZDV-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241001113283 Respirovirus Species 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 239000007766 cera flava Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- RAZBVKXQVFAIFI-UHFFFAOYSA-N Dauricoline Natural products CN1CCC2=CC(O)=C(OC)C=C2C1CC1=CC=C(O)C(OC2=CC=C(C=C2)CC2C=3C=C(C(=CC=3CCN2C)O)OC)=C1 RAZBVKXQVFAIFI-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000244939 Menispermum dauricum Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 208000020017 viral respiratory tract infection Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100447660A CN1939413B (zh) | 2005-09-26 | 2005-09-26 | 一种复方北豆根药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100447660A CN1939413B (zh) | 2005-09-26 | 2005-09-26 | 一种复方北豆根药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1939413A CN1939413A (zh) | 2007-04-04 |
CN1939413B true CN1939413B (zh) | 2011-03-23 |
Family
ID=37958115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005100447660A Expired - Fee Related CN1939413B (zh) | 2005-09-26 | 2005-09-26 | 一种复方北豆根药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1939413B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101407505B (zh) * | 2008-10-06 | 2013-08-14 | 福州璐珈医药科技有限公司 | 一种抗病毒穿心莲内酯衍生物的制备方法 |
CN104770563A (zh) * | 2014-01-09 | 2015-07-15 | 李先奇 | 一种新型无公害肥料添加剂 |
-
2005
- 2005-09-26 CN CN2005100447660A patent/CN1939413B/zh not_active Expired - Fee Related
Non-Patent Citations (8)
Title |
---|
国家药典委员会.中华人民共和国药典 一部 1995年版.化学工业出版社,1995,459. * |
国家药典委员会.中华人民共和国药典一部 1995年版.化学工业出版社,1995,459. |
国家药典委员会.国家药品标准 第44册.2003,54. * |
国家药典委员会.国家药品标准第44册.2003,54. |
邹丽.炎琥宁治疗小儿病毒性肠炎疗效观察.中国医学文摘-儿科学24 2.2005,24(2),72-73. |
邹丽.炎琥宁治疗小儿病毒性肠炎疗效观察.中国医学文摘-儿科学24 2.2005,24(2),72-73. * |
闫双银等.穿琥宁注射液的临床应用.中国药事19 5.2005,19(5),311-312. |
闫双银等.穿琥宁注射液的临床应用.中国药事19 5.2005,19(5),311-312. * |
Also Published As
Publication number | Publication date |
---|---|
CN1939413A (zh) | 2007-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101422563B (zh) | 治疗小儿咽喉炎的中药组合物及其制备方法和质量检测方法 | |
CN100457139C (zh) | 一种双黄连注射液的制备方法及其成分检测方法 | |
CN100525809C (zh) | 由黄芪、红景天和菝葜制成的药物组合物及其制备方法 | |
CN100443498C (zh) | 白薇总皂苷及其皂苷化合物在抗炎药物中的应用 | |
CN1947747B (zh) | 由木犀草素和连翘制成的药物组合物及其制备方法和用途 | |
CN1939414B (zh) | 一种具有抗菌消炎作用的药物组合物 | |
CN1939413B (zh) | 一种复方北豆根药物组合物 | |
CN1939412B (zh) | 一种由北豆根与新鱼腥草素钠制成的药物组合物 | |
CN100574757C (zh) | 乙酰半胱氨酸或其盐和抗感染药物的组合物 | |
CN1947749B (zh) | 一种由头花蓼和茯苓制成的药物组合物 | |
CN1939417B (zh) | 北豆根与金果榄或其提取物的药物组合物 | |
CN100352468C (zh) | 一种茵栀黄含片及其制备检测方法 | |
CN100482266C (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN104820029A (zh) | 一种复方鱼腥草合剂的含量检测方法 | |
CN1977886B (zh) | 一种由苦参素、灵芝和黄芪制成的药物组合物 | |
CN100493522C (zh) | 一种苦参素和多糖的药物组合物 | |
CN1961898A (zh) | 一种复方半枝莲抗肿瘤药物组合物及其制备方法 | |
CN100534476C (zh) | 由板蓝根和射干制成的药物组合物及其制备方法和用途 | |
CN100525816C (zh) | 一种头花蓼复方药物组合物及其制备方法和用途 | |
CN1969937B (zh) | 一种治疗肝炎的药物组合物 | |
CN1927250B (zh) | 一种药物组合物及其制备方法和用途 | |
CN102139002A (zh) | 黄柏多糖提取物及其制备方法和医药用途 | |
CN1939420B (zh) | 一种新的抗菌抗病毒药物组合物及其制备方法 | |
CN111588742A (zh) | 没药倍半萜提取物在制备慢性阻塞性肺病药物中的应用 | |
CN100482245C (zh) | 板蓝根和黄芩苷的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: XUAN ZHU SHANDONG MEDICINE TECHNOLOGY CO. Free format text: FORMER OWNER: CAI JUN Effective date: 20080530 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080530 Address after: Tianchen Avenue Ji'nan High-tech Development Zone in Shandong province No. 2518 post encoding: 250101 Applicant after: XUANZHU PHARMA Co.,Ltd. Address before: Tianchen Avenue Ji'nan High-tech Development Zone in Shandong province No. 2518 post encoding: 250101 Applicant before: Cai Jun |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAIAN SUSHI TECHNOLOGY TRANSFORMATION CENTER CO., Free format text: FORMER OWNER: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD. Effective date: 20131008 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 226601 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131008 Address after: 226601 No. 8 Yingbin Road, software park, Haian County, Jiangsu Province Patentee after: Haian Su Fu Technology Transfer Center Co.,Ltd. Address before: Dongchen street, Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 Patentee before: XUANZHU PHARMA Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110323 Termination date: 20160926 |
|
CF01 | Termination of patent right due to non-payment of annual fee |